oregon psilocybin

Oregon Psilocybin: Preparing for the End of Local Ownership Rules

Oregon’s rule limiting the non-resident ownership of licensed psilocybin businesses sunsets on December 31, 2024. That’s a little over six months away. Six months is not that long, especially in the context of getting to know an industry or a business, and putting a thoughtful deal together– one that will generate reasonable returns for an

psychedelics military

Psychedelics and the Military: An Unlikely Alliance

Despite decades of stigma and legal barriers, recent years have brought a profound shift in attitudes towards psychedelics. Driven by scientific inquiry and a growing recognition of their potential therapeutic benefits, the benefits of psychedelics are being explored. In this blog post, we explore the impact of an unexpected catalyst driving progress in psychedelics research–

sb 1570 arizona

Arizona’s Psilocybin Legislation

Psilocybin’s therapeutic renaissance Once relegated to the realm of recreational drug use, psilocybin is now at the forefront of a discussion on the potential therapeutic benefits of psychedelics. Arizona is the latest state to take up the discourse: its proposed Senate Bill 1570 (SB 1570) would establish licensed psychedelic-assisted therapy centers, and advance scientific research

oregon

Oregon Ketamine Clinics: New Potential Restrictions on Corporate Practice of Medicine

Should private equity be involved in health care? If so, in what types of settings? And to what extent? These are baseline considerations around a broad concept referred to as “corporate practice of medicine” (“CPOM”) that state legislatures, agencies, medical licensing boards, courts and attorneys general and grappled with for over a century. The Oregon

psychedelic assisted therapy

California Bill Proposes Psychedelic Assisted Therapy Workgroup

California recently failed at least twice in passing sweeping statewide psychedelic decriminalization bills: a) SB-58, which Governor Gavin Newsom vetoed last year, and b) SB-519, which didn’t garner enough support in the assembly the year before. It’s now trying something much more modest – convening a workgroup to study psychedelic assisted therapy. The bill at

oregon psilocybin 2023

Oregon Psilocybin: State of the State (2023)

It’s hard to believe that we are wrapping up the first year of the Oregon Psilocybin Services (OPS) program. Final rules were released at this time last year, following a protracted, two-year development period. The application window for licenses opened timely on January 2, 2023, and the Oregon Health Authority (OHA) continues to administer this

mso

Can Ketamine Clinic MSOs Succeed?

A few months ago, I wrote a post entitled “Making Money in the Psychedelics Industry Will be Harder than Cannabis.” The post was focused mostly on hardships that state-legal psilocybin businesses will face in places like Oregon and Colorado, where I think the deck is heavily stacked against them. Today I want to examine a

visions act

The VISIONS Act, Psilocybin and Federal Enforcement

Perhaps inevitably, lawmakers introduced a very skinny bill last week to protect states that legalize psilocybin from federal intervention. Specifically, it requires that: [n]o Federal funds may be used to prevent any State or unit of local government from implementing such State’s or unit of local government’s own laws that authorize the use, distribution, sale,

california psychedelics bill

Common Misconceptions About California’s New Psychedelics Bill

There is a lot of misinformation floating around online about SB-58, California’s newest psychedelics bill. Unlike the state’s last attempt, SB-58 went through both the state Senate and Assembly and is heading to Governor Newsom’s desk. So it makes sense to discuss what the bill does and doesn’t do. And no, it doesn’t legalize psychedelics.

fda approval

Will Psychedelics Be Rescheduled After FDA Approval?

A handful of entities are in various stages of the FDA approval process for MDMA and psilocybin drugs (see here and here for some of our prior analysis of the issues). FDA approval could happen in the next few years. But there’s a catch: psilocybin and MDMA are both schedule I drugs under the Controlled Substances Act (CSA).